Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[What's new in dermatological therapy?]

K Ezzedine1

  • 1Service de dermatologie, hôpital Henri-Mondor et EpiDermE, EA 7379, université Paris-Est Créteil Val-de-Marne, 94010, Créteil, France.

Annales De Dermatologie Et De Venereologie
|February 13, 2018
PubMed
Summary

Recent advancements in dermatology include new vaccines for Herpes zoster and treatments for scabies and abscesses. Biological therapies are advancing for psoriasis, atopic dermatitis, and hidradenitis suppurativa, offering hope for chronic inflammatory skin diseases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Value of tacrolimus 0.1% in the treatment of vitiligo in the era of targeted therapy.

Annales de dermatologie et de venereologie·2025
Same author

Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme.

Journal of the European Academy of Dermatology and Venereology : JEADV·2025
Same author

Protocol of a scoping review of outcome domains in dermatology.

BMJ open·2024
Same author

Association between acetaminophen use and vitiligo in US women and men.

The Australasian journal of dermatology·2023
Same author

Burden of childhood atopic dermatitis on parents: fathers' and mothers' respective feelings.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Same author

Vitiligo prevalence and quality of life among adults in Europe, Japan and the USA.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022

Area of Science:

  • Dermatology
  • Therapeutic Trials
  • Infectious Diseases

Background:

  • Recent publications highlight significant progress in therapeutic trials for infectious dermatological conditions.
  • Biological treatments are increasingly important for chronic inflammatory skin diseases like psoriasis, atopic dermatitis, and hidradenitis suppurativa, addressing unmet needs in moderate to severe cases.

Purpose of the Study:

  • To review key therapeutic advancements in dermatology from the past year.
  • To update on novel treatments for infectious diseases and chronic inflammatory conditions.
  • To discuss new approaches for rosacea and drug-induced rashes.

Main Methods:

  • Review of major publications and clinical trials in dermatological therapeutics.
  • Focus on infectious dermatology, biological treatments, and specific conditions like rosacea and erlotinib-induced rashes.
Keywords:
AbcessAbcèsAtopic dermatitisDermatite atopiqueErlotinibExanthèmeGaleHidradenitis suppurativaHidradénite suppuréePsoriasisRashRosaceaRosacéeScabiesTherapeuticThérapeutique

Related Experiment Videos

  • Analysis of randomized controlled trials and treatment guidelines.

    • Main Results:

    • The Herpes zoster subunit vaccine shows promise.
    • Effective treatments for uncomplicated abscesses and scabies are emerging.
    • Biological therapies offer new hope for psoriasis, atopic dermatitis, and hidradenitis suppurativa.
    • Isotretinoin may alter the approach to cyclin-resistant papulopustular rosacea.
    • Oral doxycycline shows potential for preventing erlotinib-induced rashes.

    Conclusions:

    • Significant therapeutic progress has been made across various dermatological fields.
    • New and existing treatments offer improved management for infectious and chronic inflammatory skin diseases.
    • These advancements promise to enhance patient quality of life and therapeutic outcomes.